Postmenopozal hastalarda raloksifen ve risedronatın kemik mineral yoğunluğu ve lipit profili üzerindeki etkinliklerinin değerlendirilmesi
[ N/A ]
Tarih
2004
Dergi Başlığı
Dergi ISSN
Cilt Başlığı
Yayıncı
Erişim Hakkı
info:eu-repo/semantics/openAccess
Özet
Amaç: Raloksifen ve risedronat monoterapilerinin, kemik mineral yoğunluğu ve serum lipit profili üzerindeki etkinliklerinin karşılaştırılması. Materyal ve Metot: Çalışmaya son âdet tarihinden itibaren en az üç yıl geçmiş, belirgin vazomotor semptomları olmayan, uterus ve överleri intakt, sağlıklı 100 postmenopozal kadın dahil edildi. 6 ay boyunca hastaların yarısına risedronat 5 mg/gün, yarısına ise raloksifen 60 mg/gün uygulandı. Gruplar tedavi sonrası, kemik mineral yoğunluğu ve serum lipit profili yüzde değişimleri açısından karşılaştırıldı. Sonuçlar: 6 aylık tedavi sonrasında risedronatın, lumbar vertebra kemik mineral yoğunluğunu raloksifenden daha fazla artırdığını (P <0.05) ancak femur boynu kemik mineral yoğunluğu üzerindeki etkinliklerinin farklı olmadığı gözlendi. Raloksifen tedavisi ile 6 ay sonunda total ve LDL kolesterol düzeylerinin, risedronattan istatistiksel anlamlı olarak daha fazla düştüğü gözlendi (P <0.05). Açlık kan şekeri, HDL kolesterol ve trigliserit düzeyindeki değişiklikler açısından gruplar arasında farklılık yoktu. Tartışma: Risedronatın özellikle lumbar vertebrada kemik mineral yoğunluğunu raloksifenden daha fazla artırmasına rağmen, raloksifenin de total ve LDL kolesterol düzeylerini düşürmesi gibi bir avantajı bulunmaktadır. Ancak, özellikle kemik mineral yoğunluğu hakkında daha kesin sonuçlar alabilmek için geniş, uzun izlem süreli çalışmalara ihtiyaç vardır.
Objective: To compare the efficacy of raloxifene and risedronate monotherapies on bone mineral density and serum lipid profile. Materials and Methods: 100 healthy postmenopausal women with intact uterus and ovaries, who had their last menstrual period at least three years ago and who had no obvious vasomotor symptoms were included in the study. The half of the pa¬tients was treated with risedronate 5 mg/day and the other half with raloxifene 60 mg/day for six months. The groups were compared according to percent changes of bone mineral density and serum lipid profile at the end of the treatment period. Results: At the end of six months, it was observed that risedronate increased the bone mineral density at lumbar spine than did raloxifene (P <0.05), whereas the efficacy on bone mineral density at femoral neck was not different. At the end of six months, it was observed that the total and LDL cholesterol levels were decreased significantly with raloxifene than with risedronate (P <0.05). There was no difference according to the fasting blood glucose, HDL cholesterol and triglyceride levels between the groups. Conclusion: Although risedronate increased the bone mineral density at lumbar spine more than raloxifene did, raloxifene has the advantage of lowering the levels of total and LDL cholesterol. However, larger studies with long-term follow-up are needed to draw exact conclusions, especially about their efficacy on bone mineral density.
Objective: To compare the efficacy of raloxifene and risedronate monotherapies on bone mineral density and serum lipid profile. Materials and Methods: 100 healthy postmenopausal women with intact uterus and ovaries, who had their last menstrual period at least three years ago and who had no obvious vasomotor symptoms were included in the study. The half of the pa¬tients was treated with risedronate 5 mg/day and the other half with raloxifene 60 mg/day for six months. The groups were compared according to percent changes of bone mineral density and serum lipid profile at the end of the treatment period. Results: At the end of six months, it was observed that risedronate increased the bone mineral density at lumbar spine than did raloxifene (P <0.05), whereas the efficacy on bone mineral density at femoral neck was not different. At the end of six months, it was observed that the total and LDL cholesterol levels were decreased significantly with raloxifene than with risedronate (P <0.05). There was no difference according to the fasting blood glucose, HDL cholesterol and triglyceride levels between the groups. Conclusion: Although risedronate increased the bone mineral density at lumbar spine more than raloxifene did, raloxifene has the advantage of lowering the levels of total and LDL cholesterol. However, larger studies with long-term follow-up are needed to draw exact conclusions, especially about their efficacy on bone mineral density.
Açıklama
Anahtar Kelimeler
Kadın Hastalıkları ve Doğum
Kaynak
ARTEMİS
WoS Q Değeri
Scopus Q Değeri
Cilt
5
Sayı
3
